What is HC Wainwright’s Estimate for VIR FY2026 Earnings?

Vir Biotechnology, Inc. (NASDAQ:VIR) – Equities researchers at HC Wainwright lifted their FY2026 earnings estimates for Vir Biotechnology in a research note issued to investors on Monday, November 9th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.89) per share for the year, up from their previous forecast of ($1.89). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.46) EPS, Q2 2027 earnings at ($0.58) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.99) EPS.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.18. The company had revenue of ($0.19) million during the quarter, compared to the consensus estimate of $0.98 million. During the same quarter last year, the firm earned ($1.17) EPS. The business’s revenue for the quarter was down 178.3% on a year-over-year basis.

VIR has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Friday, October 2nd. Zacks Research upgraded Vir Biotechnology from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 4th. Morgan Stanley lifted their price objective on Vir Biotechnology from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Tuesday. Raymond James Financial reissued a “strong-buy” rating on shares of Vir Biotechnology in a report on Monday, September 28th. Finally, Wall Street Zen upgraded shares of Vir Biotechnology from a “hold” rating to a “buy” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.57.

Vir Biotechnology Stock Performance

Shares of VIR opened at $13.15 on Wednesday. The business’s fifty day moving average price is $11.13 and its two-hundred day moving average price is $9.68. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -10.44 and a beta of 1.70. Vir Biotechnology has a 52 week low of $5.32 and a 52 week high of $14.38.

Insider Activity

In other news, EVP Vanina de Verneuil sold 2,407 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $11.10, for a total value of $26,717.70. Following the transaction, the executive vice president directly owned 110,193 shares in the company, valued at $1,223,142.30. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Vir Biotechnology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC bought a new stake in shares of Vir Biotechnology in the 2nd quarter valued at about $25,034,000. Parkman Healthcare Partners LLC bought a new position in Vir Biotechnology during the 2nd quarter worth approximately $4,843,000. ARCH Venture Management LLC bought a new position in Vir Biotechnology during the 2nd quarter worth approximately $129,353,521. BlackRock Inc. bought a new position in Vir Biotechnology during the 2nd quarter worth approximately $210,712,000. Finally, Bank of America Corp DE acquired a new position in Vir Biotechnology during the second quarter valued at approximately $11,642,000. Institutional investors own 65.32% of the company’s stock.

Key Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Vir said its combination of tobevibart and elebsiran met the primary and secondary endpoints in the pivotal Phase 3 ECLIPSE 1 trial for chronic hepatitis D. The result strengthens the case for the regimen as a potential treatment and helped drive the recent surge in the shares. Article: Vir hepatitis D drug succeeds in first pivotal study
• Positive Sentiment: Morgan Stanley raised its price target to $28 and reaffirmed an “overweight” rating; HC Wainwright also reiterated its “buy” rating with a $22 target. These upgrades reflect optimism following the trial result.
• Neutral Sentiment: The Phase 3 success is an important milestone, but the recent rally may leave the stock vulnerable to profit-taking as investors assess the treatment’s regulatory prospects, market opportunity and competition. A recent analysis also questioned whether the shares are already fairly valued after the news. Article: Vir Biotechnology: Fairly Valued After Phase 3 Success?

About Vir Biotechnology

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases and cancer. Its research draws on immunology and includes approaches such as monoclonal antibodies, small-interfering RNA therapies and T-cell-based treatments. The company’s pipeline has included programs targeting chronic hepatitis B and influenza, as well as investigational cancer therapies. Vir has also pursued research and development collaborations to advance its programs.